Anja Eberl1, Taru Hallinen2, Clas-Göran Af Björkesten1, Markku Heikkinen3, Eija Hirsi4, Mikko Kellokumpu5, Inka Koskinen6, Veikko Moilanen7, Christian Nielsen8, Heikki Nuutinen9, Ulla-Maija Suhonen10, Karri Utriainen11, Ilkka Vihriälä12, Erkki Soini2, Christina Wennerström13,14, Riikka Nissinen15, Andras Borsi16, Minni Koivunen15, Jyrki Tillonen17, Taina Sipponen1. 1. Gastroenterology, University of Helsinki and Helsinki University Hospital , Helsinki , Finland. 2. ESiOR Oy , Kuopio , Finland. 3. Department of Internal Medicine, Kuopio University Hospital , Kuopio , Finland. 4. Department of Internal Medicine, South Karelia Central Hospital , Lappeenranta , Finland. 5. Department of Internal Medicine, Lapland Central Hospital , Rovaniemi , Finland. 6. Department of Internal Medicine, Central Finland Central Hospital , Jyväskylä , Finland. 7. Department of Internal Medicine, Satakunta Central Hospital , Pori , Finland. 8. Department of Internal Medicine, Vaasa Central Hospital , Vaasa , Finland. 9. Division of Gastroenterology, Department of Medicine, Turku University Hospital , Turku , Finland. 10. Department of Internal Medicine, Kainuu Central Hospital , Kajaani , Finland. 11. Division of Gastroenterology, Department of Medicine, Turku University Hospital/Salo Hospital , Salo , Finland. 12. Department of Internal Medicine, Central Ostrobothnia Central Hospital Kokkola , Finland. 13. Medical Affairs, Janssen Cilag AB Solna , Sweden. 14. Department of Epidemiology Research, Statens Serum Institut , Denmark Copenhagen. 15. Medical Affairs, Janssen Cilag Oy , Espoo Finland. 16. Janssen Cilag Limited, EMEA HEMAR , High Wycombe , United Kingdom. 17. Department of Internal Medicine, Päijät Häme Central Hospital , Lahti Finland.
Abstract
Background: Ustekinumab (UST), a human anti-IL12/23p40 monoclonal antibody, has been approved for treatment of Crohn's Disease (CD) since the end of 2016. This nationwide noninterventional, retrospective chart review explored real-life data in patients receiving UST to provide guidance in UST treatment in the era of increasing prevalence of CD. Methods: The study assessed UST treatment patterns such as dosing frequency, concomitant medication and persistence in 48 CD patients commencing UST therapy in 12 Finnish hospitals during 2017. Clinical remission and response rates were explored using a modified Harvey-Bradshaw index (mHBI) and endoscopic response via the simple endoscopic score for Crohn's disease (SES-CD) as proportions of patients at week 16 and at the end of follow-up. Results: Forty patients (83%) continued UST-treatment at the end of follow-up. At week 16, clinical response and endoscopic healing was observed, where data were available; mHBI decreased from 9 to 3 (p = .0001) and SES-CD from 12 to 3 (p = .009). Clinical benefit was achieved by 83% (19/23) at week 16 and by 76% (16/21) at the end of follow-up. The proportion of patients using corticosteroids decreased from 48% to 25% at week 16 and to 13% at the end of the follow-up. Conclusion: UST showed to be effective and persistent, inducing short-term clinical benefit and endoscopic response in this real-life nationwide study of CD patients. Significant corticosteroid tapering in patients with highly treatment refractory and long-standing CD was observed.
Background: Ustekinumab (UST), a human anti-IL12/23p40 monoclonal antibody, has been approved for treatment of Crohn's Disease (CD) since the end of 2016. This nationwide noninterventional, retrospective chart review explored real-life data in patients receiving UST to provide guidance in UST treatment in the era of increasing prevalence of CD. Methods: The study assessed UST treatment patterns such as dosing frequency, concomitant medication and persistence in 48 CDpatients commencing UST therapy in 12 Finnish hospitals during 2017. Clinical remission and response rates were explored using a modified Harvey-Bradshaw index (mHBI) and endoscopic response via the simple endoscopic score for Crohn's disease (SES-CD) as proportions of patients at week 16 and at the end of follow-up. Results: Forty patients (83%) continued UST-treatment at the end of follow-up. At week 16, clinical response and endoscopic healing was observed, where data were available; mHBI decreased from 9 to 3 (p = .0001) and SES-CD from 12 to 3 (p = .009). Clinical benefit was achieved by 83% (19/23) at week 16 and by 76% (16/21) at the end of follow-up. The proportion of patients using corticosteroids decreased from 48% to 25% at week 16 and to 13% at the end of the follow-up. Conclusion: UST showed to be effective and persistent, inducing short-term clinical benefit and endoscopic response in this real-life nationwide study of CDpatients. Significant corticosteroid tapering in patients with highly treatment refractory and long-standing CD was observed.
Authors: Vince B C Biemans; C Janneke van der Woude; Gerard Dijkstra; Andrea E van der Meulen-de Jong; Mark Löwenberg; Nanne K de Boer; Bas Oldenburg; Nidhi Srivastava; Jeroen M Jansen; Alexander G L Bodelier; Rachel L West; Annemarie C de Vries; Jeoffrey J L Haans; Dirk de Jong; Frank Hoentjen; Marieke J Pierik Journal: Aliment Pharmacol Ther Date: 2020-05-22 Impact factor: 8.171
Authors: Sailish Honap; Susanna Meade; Hajir Ibraheim; Peter M Irving; Michael P Jones; Mark A Samaan Journal: Dig Dis Sci Date: 2021-03-16 Impact factor: 3.199
Authors: Clas-Göran Af Björkesten; Tuire Ilus; Taru Hallinen; Erkki Soini; Anja Eberl; Kalle Hakala; Mikko Heikura; Airi Jussila; Ritva Koskela; Inka Koskinen; Veikko Moilanen; Christian Nielsen; Urpo Nieminen; Heikki Nuutinen; Markku Heikkinen; Ulla-Maija Suhonen; Jyrki Tillonen; Karri Utriainen; Ilkka Vihriälä; Christina Wennerström; Andras Borsi; Riikka Nissinen; Minni R Koivunen; Taina Sipponen Journal: Eur J Gastroenterol Hepatol Date: 2020-12 Impact factor: 2.586